<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01788007</url>
  </required_header>
  <id_info>
    <org_study_id>IMQC 1220</org_study_id>
    <nct_id>NCT01788007</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the relative efficacy and safety of the test&#xD;
      formulation Imiquimod 3.75% Topical Cream to the marketed formulation Zyclara® (imiquimod)&#xD;
      3.75% Topical Cream in the treatment of actinic keratosis. Both the test and reference&#xD;
      formulations will also be compared to a placebo cream to test for superiority.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment success</measure>
    <time_frame>Week 14 (8 weeks after completion of treatment)</time_frame>
    <description>Treatment success will be defined by the proportion of patients in the per protocol population with 100% clearance of all actinic keratosis lesions within the treatment area at study week 14 (8 weeks after completion of treatment.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Superiority to placebo</measure>
    <time_frame>Week 14 (8 weeks after completion of treatment)</time_frame>
    <description>The modified intent-to-treat population and last observation carried forward will be used to evaluate the superiority of both the test and reference product to placebo for the proportion of patients showing 100% clearance of actinic keratosis lesions at week 14 (8 weeks after completion of treatment.)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">443</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Imiquimod Topical Cream 3.75%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Topical Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zyclara® (imiquimod) Topical Cream 3.75%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod Topical Cream 3.75%</intervention_name>
    <description>Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.</description>
    <arm_group_label>Imiquimod Topical Cream 3.75%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zyclara® (imiquimod) Topical Cream 3.75%</intervention_name>
    <description>Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.</description>
    <arm_group_label>Zyclara® (imiquimod) Topical Cream 3.75%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Topical Cream</intervention_name>
    <description>Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.</description>
    <arm_group_label>Vehicle Topical Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form.&#xD;
&#xD;
          -  Immunocompetent male or non-pregnant, non-lactating female at least 18 years of age.&#xD;
&#xD;
          -  Diagnosis of actinic keratosis with at least 5 and no more than 20 clinically typical,&#xD;
             visible or palpable actinic keratosis lesions, each at least 4 mm in diameter, in an&#xD;
             area that exceeds 25 cm2 on either the face (excluding ear) or balding scalp (but not&#xD;
             both.)&#xD;
&#xD;
          -  Women either must be 1 year post-menopausal, surgically sterile, or if they are of&#xD;
             child-bearing potential, they must: a) have been using systemic birth control,&#xD;
             intrauterine device, or Norplant for at least 28 days prior to the start of treatment&#xD;
             period, or used barrier methods consistently, at least 14 days before study cream&#xD;
             administration; b) had a normal menstrual cycle for the month prior to the start of&#xD;
             treatment; c) have a negative urine pregnancy test result upon entry into the study;&#xD;
             d) agree to use a medically accepted form of birth control throughout the study&#xD;
             period.&#xD;
&#xD;
          -  Free from any systemic or dermatologic disorder that, in the opinion of the&#xD;
             Investigator, will interfere with the study results or increase the risk of adverse&#xD;
             events.&#xD;
&#xD;
          -  Any skin type or race, providing the skin pigmentation will allow discernment of&#xD;
             erythema.&#xD;
&#xD;
          -  Willingness and capability to cooperate to the extent and degree required by the&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of atopic dermatitis, basal cell carcinoma, squamous cell carcinoma, eczema,&#xD;
             psoriasis, rosacea, sunburn or other possible confounding skin conditions on the face&#xD;
             or bald scalp.&#xD;
&#xD;
          -  Use within six months prior to baseline on the face or bald scalp of chemical peel,&#xD;
             dermabrasion, laser abrasion, psoralen plus ultraviolet A therapy, or ultra violet B&#xD;
             therapy.&#xD;
&#xD;
          -  Use within one month prior to baseline on the face or bald scalp of cryodestruction or&#xD;
             chemodestruction, curettage, photodynamic therapy, surgical excision, topical&#xD;
             5-fluorouracil, topical corticosteroids, topical diclofenac, topical imiquimod,&#xD;
             topical retinoids or other treatments for actinic keratosis including glycolic acids&#xD;
             or over-the-counter products containing retinol, alpha or beta hydroxy acids.&#xD;
&#xD;
          -  Use within one month prior to baseline of immunomodulators or immunosuppressive&#xD;
             therapies, interferon, oral corticosteroids or cytotoxic drugs.&#xD;
&#xD;
          -  Known allergies to imiquimod or any excipients to the test or reference creams.&#xD;
&#xD;
          -  Receiving 5-fluorouracil or other systemic cancer chemotherapy within 6 months prior&#xD;
             to study entry.&#xD;
&#xD;
          -  Any condition, medical, psychological, or social, that, in the Investigator's opinion,&#xD;
             would interfere with participation in the study.&#xD;
&#xD;
          -  Women who are pregnant or planning pregnancy or lactating during the study.&#xD;
&#xD;
          -  Participation in any investigational drug study within 30 days of enrollment or&#xD;
             previous participation in this study.&#xD;
&#xD;
          -  Employees or family members of employees of the research center or Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2013</study_first_posted>
  <last_update_submitted>January 19, 2014</last_update_submitted>
  <last_update_submitted_qc>January 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <keyword>Imiquimod Topical Cream 3.75%</keyword>
  <keyword>Zyclara® (imiquimod) Topical Cream 3.75%</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

